Undisclosed ADC-3 / Transcenta - LARVOL DELTA

Preclinical characterization of novel LIV1 antibody drug conjugates (AACR 2026) - "After conjugation into ADCs, the T1/2 of 48D6 ADC-2 ranged 10.4~11.6 days while that of SGN-LIV1A analog in mice is 3.7~3.9 days. LIV1 targeting ADC-2 and ADC-3 exhibited strong anti-tumor activities as monotherapy in PDX models and the anti-tumor activity is further enhanced by checkpoint inhibitor. ADC-2 displayed excellent tolerability profile in mice. These results support further investigation of our LIV1 ADCs in LIV1 positive solid tumors."

ADC • IO biomarker • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Solid Tumor • PD-L1